CLINICAL TRIALS PROFILE FOR EPOPROSTENOL SODIUM
✉ Email this page to a colleague
All Clinical Trials for EPOPROSTENOL SODIUM
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00373360 ↗ | Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin | Completed | United Therapeutics | Phase 4 | 2006-09-01 | The purpose of this 8-week study is to compare the effects of switching from therapy with epoprostenol or Flolan to IV Remodulin. This study will also assess the effect that changing to Remodulin will have on patient satisfaction with their treatment and impact on quality of life. |
| NCT00439946 ↗ | Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH | Terminated | United Therapeutics | Phase 4 | 2007-02-01 | The purpose of this 8-week study is to compare the effects of switching from intravenous Flolan to intravenous Remodulin therapy. Remodulin (treprostinil sodium) is an approved therapy for pulmonary arterial hypertension (PAH). Unlike Flolan, Remodulin does not need to be mixed daily and is stable at room temperature, so there is no need for ice packs. In addition, Remodulin is changed every 48hrs, instead of every 12-24 (with ice packs) or every 8 hours (without ice packs) with Flolan. Flolan is given using a type of portable medication pump called the CADD Legacy infusion pump. In this study, Remodulin will be given using a smaller and lighter medication pump called the Crono Five infusion pump. This study will also assess the effect that changing to Remodulin will have on treatment satisfaction and patient quality of life. |
| NCT00643604 ↗ | Rapid Switch From Flolan to Remodulin in the Outpatient Clinic | Terminated | United Therapeutics | Phase 4 | 2008-03-01 | The purpose of this 8-week study is to compare the effects of switching from therapy with epoprostenol or Flolan to IV Remodulin. This study will also assess the effect that changing to Remodulin will have on patient satisfaction with their treatment and impact on quality of life. |
| NCT01014156 ↗ | Epoprostenol in Pulmonary Embolism | Completed | Free University Medical Center | Phase 4 | 2004-01-01 | You are admitted to hospital because of pulmonary embolism. You are treated with anticoagulants. The investigators know that, despite this treatment, pulmonary embolism can be a threat especially if heart function is compromized. The investigators investigate a well known study drug (epoprostenol) on top of regular treatment with anticoagulants, to see if heart function can be optimized |
| NCT01105091 ↗ | Epoprostenol for Injection in Pulmonary Arterial Hypertension | Completed | Actelion | Phase 4 | 2010-03-01 | This is a prospective, multi-center, open-label, randomized, Phase IV exploratory study comparing safety, tolerability, pharmacokinetics, and effectiveness of ACT-385781A and Flolan (epoprostenol sodium) in patients with pulmonary arterial hypertension who are naïve to injectable prostanoid treatment and in need of such treatment. Approximately 30 patients from 8 U.S. clinical sites will be randomized to receive either ACT-385781A or Flolan (2:1 respectively) for 28 days of treatment. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for EPOPROSTENOL SODIUM
Condition Name
Clinical Trial Locations for EPOPROSTENOL SODIUM
Trials by Country
Clinical Trial Progress for EPOPROSTENOL SODIUM
Clinical Trial Phase
Clinical Trial Sponsors for EPOPROSTENOL SODIUM
Sponsor Name
